Sol-Gel Technologies Ltd. (NASDAQ: SLGL) announced it will discontinue development of SGT-210 for Darier disease after its Phase 1b study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE